GLP-1 medications and vision loss: the FDA warning explained.
The US Food and Drug Administration (FDA) announced on 9 November 2026 that all GLP-1 medicines must carry warnings about a potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION). The requirement covers medicines including Ozempic, Wegovy, Mounjaro and Zepbound. FDA safety communication.
What is NAION?
NAION affects the front of the optic nerve when its blood supply is reduced. It typically causes sudden, painless vision loss in one eye, sometimes described as blurred or cloudy vision. People with type 2 diabetes already have an increased risk of the condition, according to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The condition can cause permanent visual impairment. Australia’s Therapeutic Goods Administration (TGA) states that no treatment has been shown to improve visual acuity outcomes in NAION. TGA safety update.
What did the FDA’s review find?
An analysis of 126 randomised controlled trials, involving 134,253 patients, identified 15 probable NAION events. Rates were 6.4 per 100,000 person-years among GLP-1 users and 3.8 among patients receiving placebo or another diabetes medicine. Person-years combine the number of participants with their follow-up time.
Findings varied between comparison groups in the FDA’s real-world study. Its animal-data review did not identify a mechanism explaining the potential risk. The agency requires NAION information in the Warnings and Precautions section of labelling. Read the FDA’s evidence review.
How does this compare with UK and Australian guidance?
The MHRA issued semaglutide-specific advice on 5 February 2026, covering Ozempic, Wegovy and Rybelsus. Other GLP-1 medicines were outside that review’s scope. The UK guidance advises discontinuing semaglutide if NAION is confirmed. MHRA guidance.
Australia published class-wide safety information on 23 July 2026. Its TGA update also advises urgent eye assessment for sudden vision loss and discontinuation of semaglutide if NAION is confirmed. These are separate regulatory actions, with different scopes. Australian guidance.
What should patients and eye care teams know?
For UK patients taking semaglutide, the MHRA advises urgently attending eye casualty or A&E for sudden vision loss or rapidly worsening eyesight. A routine appointment is not the appropriate response to those symptoms.
The MHRA also asks clinicians to enquire about privately prescribed semaglutide, which may be missing from a patient’s medical record, and to report suspected adverse reactions through the Yellow Card scheme. Read the patient and professional advice.
Following a NAION event, the FDA advises patients to discuss continuing or stopping their medicine with their healthcare professional. FDA patient advice.
Stay connected with Vision Executives.
Follow Vision Executives on LinkedIn to stay up to date with the latest eye care industry news, insights and job vacancies across ophthalmology, optometry, optical retail and medical technology.